发明名称 Ganglioside Transmucosal Formulations
摘要 A transmucosal formulation comprising a ganglioside and a mucosal absorption enhancer, as well as a method of treating or preventing Parkinson's disease in a human patient in need thereof comprising parenterally administering such a transmucosal formulation to said patient.
申请公布号 US2015283158(A1) 申请公布日期 2015.10.08
申请号 US201414520206 申请日期 2014.10.21
申请人 LZ Therapeutics, Inc. 发明人 Koleng John J.;Florentine Robert;Anderson David W.;Anderson David W.
分类号 A61K31/7028;A61M13/00;A61M31/00;A61M15/00;A61K45/06;A61K9/00 主分类号 A61K31/7028
代理机构 代理人
主权项 1. A pharmaceutical composition for treatment or prevention of a central nervous system (CNS) disease or condition in a human patient amenable to treatment by therapeutic administration of an GM1, comprising a formulation for transmucosal administration comprising: GM1 and at least one permeation-enhancing agent effective to enhance transmucosal drug uptake; at least one buffer; at least one solvent; and at least one osmolarity agent.
地址 Malvern PA US